Celadon Pharmaceuticals PLC (CEL) - Total Liabilities
Based on the latest financial reports, Celadon Pharmaceuticals PLC (CEL) has total liabilities worth GBX6.01 Million GBX (≈ $731.12 USD) as of June 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Celadon Pharmaceuticals PLC to evaluate the company's liquid asset resilience ratio.
Celadon Pharmaceuticals PLC - Total Liabilities Trend (2019–2023)
This chart illustrates how Celadon Pharmaceuticals PLC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Celadon Pharmaceuticals PLC (CEL) total assets.
Celadon Pharmaceuticals PLC Competitors by Total Liabilities
The table below lists competitors of Celadon Pharmaceuticals PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CAP-XX Limited
LSE:CPX
|
UK | GBX3.74 Million |
|
FOXO Technologies Inc.
NYSE MKT:FOXO
|
USA | $36.15 Million |
|
Nexus Infrastructure plc
LSE:NEXS
|
UK | GBX24.47 Million |
|
Frontier IP Group Plc
LSE:FIPP
|
UK | GBX12.40 Million |
|
Slate Grocery REIT
TO:SGR-U
|
Canada | $1.53 Billion |
|
Viaplay Group AB Series A
ST:VPLAY-A
|
Sweden | Skr16.74 Billion |
|
Induction Healthcare Group PLC
LSE:INHC
|
UK | GBX8.90 Million |
|
Tern Plc
LSE:TERN
|
UK | GBX607.41K |
Liability Composition Analysis (2019–2023)
This chart breaks down Celadon Pharmaceuticals PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Celadon Pharmaceuticals PLC (CEL) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Celadon Pharmaceuticals PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Celadon Pharmaceuticals PLC (2019–2023)
The table below shows the annual total liabilities of Celadon Pharmaceuticals PLC from 2019 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | GBX6.04 Million ≈ $734.89 |
-2.80% |
| 2022-12-31 | GBX6.21 Million ≈ $756.06 |
+3050.65% |
| 2021-12-31 | GBX197.23K ≈ $24.00 |
-94.74% |
| 2020-12-31 | GBX3.75 Million ≈ $456.51 |
+44.19% |
| 2019-12-31 | GBX2.60 Million ≈ $316.61 |
-- |
About Celadon Pharmaceuticals PLC
Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products. Its products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.